A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Study Completion Date

2012-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is selecting second line therapy for patients with pancreatic cancer using molecular profiling will improve 1 year survival.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Following first-line therapy with a gemcitabine based regimen, a significant number of patients will maintain an adequate performance status and be able to tolerate a second-line therapy. A recent phase III trial randomized patients to either 5-flurouracil (5FU), folinic acid or to the addition of weekly oxaliplatin to the same regimen of 5FU/folinic acid. The interim results showed a statistically significant survival advantage for the oxaliplatin containing arm (26 versus 13 weeks, P= 0.014). However the outcome of patients who have progressed on a first-line gemcitabine regimen is still poor with median survival of about 2-6 months.

Almost all patients with advanced APC, treated with gemcitabine alone or a gemcitabine based combination therapy will exhibit resistance to therapy. In patients treated with gemcitabine alone, the time to progression (TTP) is about 3-4 months. Thus most patients will exhibit progression and /or toxicity and will require second line therapy at 4-6 months into first line therapy. The best one year survival reported in a phase II trial is only 24%. However there is no standard second line therapy for APC, a rapid progression of tumor is seen in this setting, and new strategies based on rational target identification are needed. In this study we propose to select therapy based on the molecular profiling of each patients tumor.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Previously Treated Metastatic Pancreatic Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

pancreatic cancer molecular profiling SU2C Second line therapy Stage 4

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank

FDA approved drugs as indicated by molecular profiling

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

FDA approved drugs as indicated by molecular profiling

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* metastatic adenocarcinoma of the pancreas
* male or non-pregnant female
* 18 years of age or greater
* one prior therapy for the treatment of metastatic disease
* must start continuation therapy within 9 months of starting first line treatment
* have adequate organ and bone marrow function
* must have a Karnofsky performance status greater than or equal to 70
* one or more metastatic tumors measurable by CT scan and accessible for biopsy

Exclusion Criteria

* operable or locally advanced pancreatic cancer
* metastatic tumor that is not amendable to biopsy
* known brain mets unless previously treated and well controlled
* active, uncontrolled bacterial, viral or fungal infections
* known infection with HIV, hepatitis B or hepatitis C
* pregnant or breast-feeding patients

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

TGen

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ramesh Ramanathan, MD

Role: PRINCIPAL_INVESTIGATOR

TGen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

TGen Clinical Research Services at Scottsdale Healthcare

Scottsdale, Arizona, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SU2C-001

Identifier Type: -

Identifier Source: org_study_id